Literature DB >> 10997989

Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens.

J E Berry1, C M Murphy, G A Smith, E Ranasinghe, R Finberg, J Walton, J Brown, C Navarrete, P Metcalfe, W H Ouwehand.   

Abstract

The glycosylphosphatidylinositol-linked platelet protein CD109 carries the biallelic alloantigen system Gov. There is limited information on the incidence of Gov alloantibodies in neonatal alloimmune thrombocytopenia (NAITP), post-transfusion purpura (PTP) and platelet refractoriness. We adapted the monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay to the detection of Gov antibodies and determined their incidence in 605 archived samples (112 with HPA antibodies) referred for the aforementioned conditions. Here, we show that CD109 expression was reduced upon platelet storage in saline or by cryopreservation, but was stable when stored as whole blood or therapeutic platelet concentrate. Fourteen of the 605 samples contained Gov alloantibodies (anti-Gova, n = 10; anti-Govb, n = 4), with the majority in platelet refractoriness (n = 9) and, of the remaining five, four in NAITP and one in PTP. In seven cases, no other HPA antibodies were detected, three being NAITP cases. The incidence of Gov antibodies was significantly lower than HPA-1 system antibodies (n = 87), but equalled the number of HPA-5 system antibodies (n = 14) and outnumbered HPA-2 and -3 system antibodies (10 altogether).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997989     DOI: 10.1046/j.1365-2141.2000.02170.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers.

Authors:  Cedric Ghevaert; Nina Herbert; Louise Hawkins; Nicola Grehan; Philip Cookson; Steve F Garner; Abigail Crisp-Hihn; Paul Lloyd-Evans; Amanda Evans; Kottekkattu Balan; Willem H Ouwehand; Kathryn L Armour; Mike R Clark; Lorna M Williamson
Journal:  Blood       Date:  2013-05-08       Impact factor: 22.113

Review 2.  Advances in alloimmune thrombocytopenia: perspectives on current concepts of human platelet antigens, antibody detection strategies, and genotyping.

Authors:  Tomoya Hayashi; Fumiya Hirayama
Journal:  Blood Transfus       Date:  2015-04-30       Impact factor: 3.443

3.  Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.

Authors:  Cedric Ghevaert; David A Wilcox; Juan Fang; Kathryn L Armour; Mike R Clark; Willem H Ouwehand; Lorna M Williamson
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

4.  Human Platelet Antigens in Brazilian Multiethnic Populations: Occurrence of Regional Variation and Frequency in a Large Urban Center (Belo Horizonte).

Authors:  Maria Clara Fernandes Silva-Malta; Lucas Gabriel Tavares de Oliveira; Luísa Ferreira Barreiros; Dilson Rocha do Amaral; Marina Lobato Martins
Journal:  Transfus Med Hemother       Date:  2018-05-11       Impact factor: 3.747

5.  A first WHO reference reagent for the detection of anti-human platelet antigen-15b.

Authors:  Giles Sharp; Anthony Poles; Lucy Studholme
Journal:  Vox Sang       Date:  2021-06-23       Impact factor: 2.996

6.  Human platelet antigen alleles in 998 Taiwanese blood donors determined by sequence-specific primer polymerase chain reaction.

Authors:  Shun-Chung Pai; Thierry Burnouf; Jen-Wei Chen; Liang-In Lin
Journal:  Biomed Res Int       Date:  2013-06-20       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.